Literature DB >> 16860162

Pulmonary outcomes in bronchopulmonary dysplasia.

Anita Bhandari1, Howard B Panitch.   

Abstract

The incidence of bronchopulmonary dysplasia (BPD), defined as oxygen need at 36 weeks of postmenstrual age, is about 30% for infants with birth weights <1000 g. BPD is associated with persistent structural changes in the lung that result in significant effects on lung mechanics, gas exchange, and pulmonary vasculature. Up to 50% of infants with BPD require readmission to the hospital for lower respiratory tract illness in the first year of life. Long-term measurements of lung function in BPD include normalization of pulmonary mechanics and some lung volumes over time as somatic and lung growth occur, whereas abnormality of small airway function persists. The majority of data reveals no long-term decrease in exercise capacity. Mild to moderate radiological abnormalities persist. BPD is a result of dynamic processes involving inflammation, injury, repair, and maturation. Infants with BPD have significant pulmonary sequelae during childhood and adolescence, and continued surveillance of young adults with BPD is critical.

Entities:  

Mesh:

Year:  2006        PMID: 16860162     DOI: 10.1053/j.semperi.2006.05.009

Source DB:  PubMed          Journal:  Semin Perinatol        ISSN: 0146-0005            Impact factor:   3.300


  44 in total

1.  Relationship between Epigenetic Maturity and Respiratory Morbidity in Preterm Infants.

Authors:  Anna K Knight; Alicia K Smith; Karen N Conneely; Philippa Dalach; Yuk J Loke; Jeanie L Cheong; Peter G Davis; Jeffrey M Craig; Lex W Doyle; Christiane Theda
Journal:  J Pediatr       Date:  2018-04-25       Impact factor: 4.406

2.  Polysomnography in preterm infants and children with chronic lung disease.

Authors:  Sharon A McGrath-Morrow; Timothy Ryan; Brian M McGinley; Sande O Okelo; Laura M Sterni; J Michael Collaco
Journal:  Pediatr Pulmonol       Date:  2011-08-03

3.  The renin angiotensin system in liver and lung: impact and therapeutic potential in organ fibrosis.

Authors:  Amal Abdul-Hafez; Tarek Mohamed; Hanan Omar; Mohamed Shemis; Bruce D Uhal
Journal:  J Lung Pulm Respir Res       Date:  2018-02-27

4.  A new infant hybrid respiratory simulator: preliminary evaluation based on clinical data.

Authors:  Barbara Stankiewicz; Krzysztof J Pałko; Marek Darowski; Krzysztof Zieliński; Maciej Kozarski
Journal:  Med Biol Eng Comput       Date:  2017-03-25       Impact factor: 2.602

Review 5.  Sex differences and sex steroids in lung health and disease.

Authors:  Elizabeth A Townsend; Virginia M Miller; Y S Prakash
Journal:  Endocr Rev       Date:  2012-01-12       Impact factor: 19.871

Review 6.  Strategies to enhance paracrine potency of transplanted mesenchymal stem cells in intractable neonatal disorders.

Authors:  Won Soon Park; So Yoon Ahn; Se In Sung; Jee-Yin Ahn; Yun Sil Chang
Journal:  Pediatr Res       Date:  2017-11-01       Impact factor: 3.756

7.  Neonatal hyperoxia causes pulmonary vascular disease and shortens life span in aging mice.

Authors:  Min Yee; R James White; Hani A Awad; Wendy A Bates; Sharon A McGrath-Morrow; Michael A O'Reilly
Journal:  Am J Pathol       Date:  2011-05-06       Impact factor: 4.307

Review 8.  Postnatal inflammation in the pathogenesis of bronchopulmonary dysplasia.

Authors:  Vineet Bhandari
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2014-02-27

9.  Neonatal hyperoxia enhances the inflammatory response in adult mice infected with influenza A virus.

Authors:  Michael A O'Reilly; Shauna H Marr; Min Yee; Sharon A McGrath-Morrow; B Paige Lawrence
Journal:  Am J Respir Crit Care Med       Date:  2008-02-21       Impact factor: 21.405

10.  Mig-6 is required for appropriate lung development and to ensure normal adult lung homeostasis.

Authors:  Nili Jin; Sung-Nam Cho; M Gabriela Raso; Ignacio Wistuba; Yvonne Smith; Yanan Yang; Jonathan M Kurie; Rudolph Yen; Christopher M Evans; Thomas Ludwig; Jae-Wook Jeong; Francesco J DeMayo
Journal:  Development       Date:  2009-08-26       Impact factor: 6.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.